ES2051920T3 - Una composicion farmaceutica y su procedimiento de preparacion. - Google Patents
Una composicion farmaceutica y su procedimiento de preparacion.Info
- Publication number
- ES2051920T3 ES2051920T3 ES89109381T ES89109381T ES2051920T3 ES 2051920 T3 ES2051920 T3 ES 2051920T3 ES 89109381 T ES89109381 T ES 89109381T ES 89109381 T ES89109381 T ES 89109381T ES 2051920 T3 ES2051920 T3 ES 2051920T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical composition
- preparation procedure
- dimetilo
- sucinato
- fenilmetil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13226288 | 1988-05-30 | ||
JP1050471A JP2528706B2 (ja) | 1988-05-30 | 1989-03-02 | ジヒドロピリジン化合物の製剤組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2051920T3 true ES2051920T3 (es) | 1994-07-01 |
Family
ID=26390939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES89109381T Expired - Lifetime ES2051920T3 (es) | 1988-05-30 | 1989-05-24 | Una composicion farmaceutica y su procedimiento de preparacion. |
Country Status (8)
Country | Link |
---|---|
US (1) | US4983593A (forum.php) |
EP (1) | EP0344603B1 (forum.php) |
JP (1) | JP2528706B2 (forum.php) |
CA (1) | CA1332152C (forum.php) |
DE (1) | DE68900356D1 (forum.php) |
ES (1) | ES2051920T3 (forum.php) |
GR (1) | GR3003615T3 (forum.php) |
NZ (1) | NZ229309A (forum.php) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW212139B (forum.php) * | 1991-04-15 | 1993-09-01 | Yamanouchi Pharma Co Ltd | |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US6726930B1 (en) * | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
TW487582B (en) * | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
ES2184063T3 (es) * | 1996-03-18 | 2003-04-01 | Nissan Chemical Ind Ltd | Procedimiento de produccion de preparaciones de clorhidrato de efonidipina. |
MX9801835A (es) | 1996-07-08 | 1998-08-30 | Mendell Co Inc Edward | Matriz de liberacion sostenida para medicamentos insolubles de dosis altas. |
EP0901786B1 (en) | 1997-08-11 | 2007-06-13 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
EP1741424B1 (en) | 1997-08-11 | 2018-10-03 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailabilty |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
US6350786B1 (en) † | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
DE60039377D1 (de) | 1999-02-09 | 2008-08-21 | Pfizer Prod Inc | Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit |
US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
DE60042352D1 (de) * | 1999-02-10 | 2009-07-23 | Pfizer Prod Inc | Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten |
EP1027887B1 (en) * | 1999-02-10 | 2008-08-13 | Pfizer Products Inc. | Matrix controlled release device |
ATE400252T1 (de) | 1999-02-10 | 2008-07-15 | Pfizer Prod Inc | Pharmazeutische feste dispersionen |
IL143375A0 (en) | 1999-09-30 | 2002-04-21 | Penwest Pharmaceuticals Co | Sustained release matrix systems for highly soluble drugs |
ES2240222T3 (es) * | 1999-12-20 | 2005-10-16 | Nicholas J. Kerkhof | Procedimiento para producir particulas nanometricas mediante secado por pulverizacion en lecho fluidizado. |
IL149186A0 (en) | 1999-12-23 | 2002-11-10 | Pfizer Prod Inc | Pharmaceutical compositions providing enhanced drug concentrations |
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
AU2002212102A1 (en) * | 2000-11-08 | 2002-05-21 | Aeromatic-Fielder Ag | A process for production of particles for pharmaceutical compositions having increased bioavailability |
DE10058772A1 (de) * | 2000-11-27 | 2002-06-06 | Falk Pharma Gmbh | Verfahren zur Herstellung leicht löslicher Arzneimittelformulierungen und entsprechende Formulierungen |
US20030170309A1 (en) * | 2001-06-22 | 2003-09-11 | Babcock Walter C. | Pharmaceutical compositions containing polymer and drug assemblies |
CA2450957A1 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
WO2005117834A1 (en) * | 2004-05-27 | 2005-12-15 | Janssen Pharmaceutica N.V. | Solid dispersions of a basic drug compound and a polymer containing acidic groups |
DE602005010074D1 (de) | 2004-05-28 | 2008-11-13 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer |
US20080096924A1 (en) * | 2004-12-17 | 2008-04-24 | Ono Pharmaceutical Co., Ltd. | Amorphous Composition |
WO2007029660A1 (ja) * | 2005-09-06 | 2007-03-15 | Astellas Pharma Inc. | 腸溶性基剤が表面に吸着した難溶性薬物の微小粒子 |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009038112A1 (ja) | 2007-09-21 | 2009-03-26 | Shionogi & Co., Ltd. | Npyy5受容体拮抗剤を含有する固形製剤 |
US9149434B2 (en) | 2007-12-03 | 2015-10-06 | Tomita Pharmaceutical Co., Ltd. | Core particle for pharmaceutical preparation |
EP2291079B1 (en) * | 2008-05-14 | 2013-04-24 | Merck Sharp & Dohme Corp. | Formulations for cathepsin k inhibitors |
CN102361870B (zh) | 2009-04-03 | 2015-11-25 | 豪夫迈罗氏公司 | 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途 |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
WO2011031620A1 (en) * | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
NZ599866A (en) | 2009-11-06 | 2014-09-26 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
CN103153343B (zh) | 2010-06-14 | 2015-02-11 | 陶氏环球技术有限责任公司 | 具有提高的醋酸酯和琥珀酸酯取代的醋酸羟丙基甲基纤维素琥珀酸酯 |
MA34948B1 (fr) | 2011-02-07 | 2014-03-01 | Plexxikon Inc | Composes et procedes de modulation de kinase, et leurs indications |
AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
EP2654726A4 (en) | 2011-03-08 | 2013-10-30 | Zalicus Pharmaceuticals Ltd | SOLID DISPERSION FORMULATIONS AND METHODS OF USE |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
EP2837391B1 (en) | 2013-08-12 | 2017-05-10 | Shin-Etsu Chemical Co., Ltd. | Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate |
CN113209024A (zh) | 2013-12-31 | 2021-08-06 | 阿森迪亚制药有限责任公司 | 疏水性化合物的药物组合物 |
EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
SG11201811491YA (en) | 2016-06-27 | 2019-01-30 | Achillion Pharmaceuticals Inc | Quinazoline and indole compounds to treat medical disorders |
PT3985002T (pt) | 2017-03-01 | 2025-08-29 | Achillion Pharmaceuticals Inc | Compostos farmacêuticos de arilo, heteroarilo e heterocíclicos para tratamento de distúrbios médicos |
WO2018175648A1 (en) * | 2017-03-21 | 2018-09-27 | Bioduro, Llc | Gastrointestinal-protective formulations for oral delivery of proteins and peptides |
WO2020041301A1 (en) | 2018-08-20 | 2020-02-27 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ, インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
JP7504088B2 (ja) | 2018-10-16 | 2024-06-21 | ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド | 医学的障害の治療のための一酸化炭素プロドラッグ |
US20230105108A1 (en) | 2019-12-19 | 2023-04-06 | Georgia State University Research Foundation, Inc. | Compounds for the treatment of bacterial infections and potentiation of antibiotics |
EP4107166A4 (en) | 2020-02-20 | 2024-06-26 | Achillion Pharmaceuticals, Inc. | Heteroaryl compounds for treatment of complement factor d mediated disorders |
US20250171423A1 (en) | 2020-09-23 | 2025-05-29 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5948810A (ja) | 1982-09-10 | 1984-03-21 | Sony Corp | 磁性記録体におけるデ−タのマスク及び再生方法 |
JPS62123117A (ja) | 1985-11-22 | 1987-06-04 | Nippon Chemiphar Co Ltd | 塩酸ニカルジピン経口用組成物 |
CN1016063B (zh) * | 1986-01-22 | 1992-04-01 | 日产化学工业株式会社 | 二氢吡啶-5-膦酸环亚丙基酯的制备 |
IL81419A0 (en) * | 1986-01-30 | 1987-08-31 | Syntex Inc | Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation |
-
1989
- 1989-03-02 JP JP1050471A patent/JP2528706B2/ja not_active Expired - Lifetime
- 1989-05-24 ES ES89109381T patent/ES2051920T3/es not_active Expired - Lifetime
- 1989-05-24 EP EP89109381A patent/EP0344603B1/en not_active Expired - Lifetime
- 1989-05-24 DE DE8989109381T patent/DE68900356D1/de not_active Expired - Lifetime
- 1989-05-25 CA CA000600631A patent/CA1332152C/en not_active Expired - Lifetime
- 1989-05-26 NZ NZ229309A patent/NZ229309A/en unknown
- 1989-05-30 US US07/358,144 patent/US4983593A/en not_active Expired - Lifetime
-
1992
- 1992-01-22 GR GR920400057T patent/GR3003615T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA1332152C (en) | 1994-09-27 |
NZ229309A (en) | 1991-06-25 |
US4983593A (en) | 1991-01-08 |
GR3003615T3 (forum.php) | 1993-03-16 |
JPH0249728A (ja) | 1990-02-20 |
DE68900356D1 (de) | 1991-11-28 |
EP0344603B1 (en) | 1991-10-23 |
JP2528706B2 (ja) | 1996-08-28 |
EP0344603A1 (en) | 1989-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2051920T3 (es) | Una composicion farmaceutica y su procedimiento de preparacion. | |
IT8819693A0 (it) | Apparecchio atto ad operare, in modo pressoche' istantaneo, la distruzione completa dell'ago di siringhe per iniezione, subito dopo il loro impiego. | |
RU94022479A (ru) | Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови, фармацевтический препарат | |
DE3676670D1 (de) | Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung. | |
DE69011059D1 (de) | Heterozyklische Acylaminothiazolderivate, ihre Herstellung und diese enthaltende pharmazeutische Zubereitungen. | |
DK395689D0 (da) | Pharmaceutisk tilberedning til behandling af diabetes mellitus | |
GR1001503B (el) | Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών. | |
NO842290L (no) | Fremgangsmaate for fremstilling av preparater inneholdende oralt antidiabetisk aktive stoffer | |
ES2161697T3 (es) | Peptidos agonistas de amilina y usos de los mismos. | |
SE8504945L (sv) | Farmaceutiska kompositioner innehallande antracyklinglykosider | |
DE3783356D1 (de) | Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate. | |
ES2067250T5 (es) | Preparado farmaceutico sin disolventes para administracion oral, con liberacion retardada de la sustancia activa y procedimiento para su fabricacion. | |
KR910000703A (ko) | 테트라졸 자극성 아미노산 수용체의 길항물질 | |
PT101725A (pt) | Processo para a preparacao de um composto de diarilo anti-aterosclerotico e de composicoes farmaceuticas que o contem | |
SE8804628D0 (sv) | New compounds | |
Kastin et al. | Inhibition of MSH release in frogs by direct application of L-prolyl-L-leucylglycinamide to the pituitary | |
ATE67406T1 (de) | Nicorandil enthaltende zubereitung zum einspritzen. | |
AR012997A1 (es) | Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene. | |
LV10267A (lv) | Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai | |
DE68905613D1 (de) | Pharmazeutische zubereitung. | |
ATE66615T1 (de) | Pharmazeutische zubereitung fuer eine parenterale verabreichung, die calcitonin als wirkstoff enthaelt. | |
KR940005283A (ko) | 활성 성분으로 글리센틴을 함유하는 약제 | |
AR012996A1 (es) | Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador. | |
EA200000141A1 (ru) | Способ лечения диабета тиазолидиндионом и сульфонилмочевиной | |
NO180269C (no) | Analogifremgangsmåte for fremstilling av terapeutisk akive aminoketonderivater |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 344603 Country of ref document: ES |